Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹63,973 Cr
verified against source
Revenue YoY
5.6%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
TCS reported Q3 FY25 revenue of INR 63,973 crore, up 5.6% YoY, with operating margin expanding 40 bps sequentially to 24.5%. The highlight was a record TCV of $10.2 billion, broad-based across industries and geographies, with BFSI contributing $3.2 billion. Management noted early signs of discretionary spending revival, particularly in BFSI and retail, and a shortening of deal cycles. AI/GenAI deal momentum continues, with agentic AI gaining traction. However, North America revenue declined 2.3% YoY, and headcount fell to 607,354. The BSNL contract is 70% complete and will taper from Q4. Management expects CY25 to be better than CY24, driven by improving demand and strong pipeline. Key risk: macro uncertainty from US trade policies could dampen discretionary recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management aims to exit Q4 at 26% operating margin, within the 26%-28% aspirational band, driven by operating efficiencies and BSNL tapering.
- The BSNL contract is 70% complete; revenue will start tapering in Q4 and may extend to Q2 FY26. Management expects to replace most of it via other opportunities.
- Management expects stronger growth in CY25 vs CY24, driven by early discretionary recovery and strong deal pipeline, despite BSNL headwinds.
- Preparations underway to onboard a higher number of campus hires next fiscal year, signaling confidence in future demand.
Risks flagged
- Potential increase in inflation due to trade tariffs or uncertain government policies could dampen discretionary spending recovery.
- The BSNL contract tapering from Q4 could create a revenue gap; management is confident of replacement but execution risk remains.
- North America revenue declined 2.3% YoY, and TTH slowed considerably in the US due to market-specific issues and strained client profitability.
- Life sciences healthcare declined 4.3% YoY; recovery depends on policy clarity in the US, which is uncertain.
Key quotes
- The highlight of the quarter was our exceptionally strong and broad-based TCV at $10.2 billion.
- We are seeing early signs of revival in discretionary spend in BFSI and retail.
- Agentic AI represents the next step of maturity in the exponentially evolving space of AI.
Research modules